Stay updated on LY3484356 in Advanced Breast or Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the LY3484356 in Advanced Breast or Endometrial Cancer Clinical Trial page.

Latest updates to the LY3484356 in Advanced Breast or Endometrial Cancer Clinical Trial page
- Check5 days agoChange DetectedSite-wide updates include adding a new revision note (v3.4.2) and removing the previous funding-status notice (v3.4.1); no clinical study details, eligibility criteria, or results on the page are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check12 days agoChange DetectedNotice about government funding lapse and NIH operations was added, and the site revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.2%

- Check19 days agoChange DetectedThe page now shows the glossary by default and updates the metadata labels to 'Last Update Submitted that Met QC Criteria' with Revision: v3.4.0, replacing the previous lowercase variant and Revision: v3.3.4.SummaryDifference0.1%

- Check33 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4, reflecting a minor internal update to the page's release notes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedAdded a new publication citation to the Publications section for the EMBER study: Bhave M, Jhaveri KL, Kaufman PA, et al., Imlunestrant in combination with HER2-directed therapy, Breast Cancer Research, 2025 (online ahead of print).SummaryDifference0.0%

- Check54 days agoChange DetectedAdded a Locations section listing study sites by country and region across multiple countries.SummaryDifference2%

Stay in the know with updates to LY3484356 in Advanced Breast or Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LY3484356 in Advanced Breast or Endometrial Cancer Clinical Trial page.